Biography
In her research, Feng studies transplantation tolerance, a transplant recipient's ability to maintain normal organ function with minimal or no use of immunosuppressive drugs. With funding from the National Institutes of Health, she has led several multicenter clinical trials to study tolerance in both adult and pediatric liver transplant recipients.
Feng is a graduate of Harvard College, where she received the prestigious Marshall Scholarship. She completed a doctorate in molecular biology at the University of Cambridge and earned her medical degree at Stanford University School of Medicine. She completed a general surgery residency at Brigham and Women's Hospital, followed by a transplant fellowship at UCSF.
Feng has held leadership positions in prominent professional societies and with the United Network for Organ Sharing. She has organized several national conferences addressing issues critical to the transplantation community, serves on the editorial board of the New England Journal of Medicine and is the editor-in-chief for the American Journal of Transplantation.
Dr. Feng was elected to be a member of the National Academy of Medicine in 2023.
Videos
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of California | Diversity, Equity, and Inclusion Champion Training | 12/2020 | |
Stanford University | M.D. | School of Medicine | 1990 |
Board Certifications
American Board of Surgery, 1996
Collaboration Interests
I am interested in:
- physician scientist
Clinical Expertise
Expanded Criteria Donor Kidney Transplantation
Immunosuppression for Liver Transplantation
Kidney Transplantation
Liver Transplantation
MELD Allocation and Living Donor Liver Transplantation
Pancreas Transplantation
Clinical Trials
- EVR and EPO for Liver Transplant Tolerance (NCT06832189)Related Conditions: Liver Transplant| Start Date: | End Date:
- Related Conditions: Liver Transplant| Start Date: | End Date:
- Liver Transplantation With Tregs at UCSF (NCT03654040)Related Conditions: Liver Transplant| Start Date: | End Date:
- Related Conditions: Liver Transplant| Start Date: | End Date:
- Related Conditions: Liver Transplant| Start Date: | End Date:
- Related Conditions: Liver Transplant| Start Date: | End Date:
Program Affiliations
- Clinical Fellowship, Division of Transplantation
- The Liver Center at UCSF
- Director, Expanded Criteria Donor Kidney Transplant Program, University of California, San Francisco
- UCSF Hellen Diller Family Comprehensive Cancer Center
In the News
Grants and Funding
- PROSPECTIVE LONGITUDINAL STUDY OF IWITH SCREEN FAILURES SECONDARY TO HISTOPATHOLOGY | NIH | 2017-08-10 - 2021-07-31 | Role: Principal Investigator
- Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation | NIH | 2014-06-01 - 2021-05-31 | Role: Principal Investigator
- Polyclonal Tregs to Promote Tolerance in Pediatric Liver Transplant Recipients | NIH | 2013-02-01 - 2020-01-31 | Role: Principal Investigator
- Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients | NIH | 2012-07-27 - 2019-06-30 | Role: Principal Investigator
- Donor-Specific Regulatory T Cell Therapy in Liver Transplantation | NIH | 2012-04-01 - 2014-03-31 | Role: Principal Investigator
- Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients | NIH | 2009-09-30 - 2013-03-31 | Role: Principal Investigator
Research Narrative
Dr. Feng's research interest focuses on transplant immunology, with a particular focus on determinants of organ tolerance. She is also investigating novel immunosuppressive regimens and pursuing immunosuppression withdrawal in selected liver transplant recipients. By studying the immune profiles of transplant patients who are successfully weaned from immunosuppressants, she and her group hope to predict prospectively which patients may be good candidates for immunosuppression withdrawal.
Research Interests
- Immunosuppression Withdrawal for Stable Pediatric Living Donor Liver Transplant Recipients
- Immunosuppression Withdrawal and Identification of a Profile Predictive of Tolerance
- Defining the Optimal Immunosuppression for Specific Transplant Settings
- Expanded Criteria Donors
- Novel Immunosuppression Strategies for Liver Transplantation
- Strategies to Decrease Ischemia Reperfusion Injury to Improve Early Graft Function after Kidney Transplantation
- Improving Long-term Outcomes for Liver Transplant Recipients
Publications
- Clinical Practice Recommendations on the Effect of COVID-19 Vaccination Strategies on Outcomes in Solid Organ Transplant Recipients.| | PubMed
- Defining an NK Cell-enriched Rejection-like Phenotype in Liver Transplant Biopsies From the INTERLIVER Study.| | PubMed
- Donor-specific immune senescence as a candidate biomarker of operational tolerance following liver transplantation in adults: Results of a prospective, multicenter cohort study.| | PubMed
- Novel autoantibody targets identified in patients with autoimmune hepatitis (AIH) by PhIP-Seq reveals pathogenic insights.| | PubMed
- The type, duration, and severity of pretransplant kidney injury predict prolonged kidney dysfunction after liver transplantation.| | PubMed
- The future of liver transplantation.| | PubMed
- Banff 2022 Liver Group Meeting report: Monitoring long-term allograft health.| | PubMed
- The Banff process-Reloaded: A joint initiative from the Banff Foundation for Allograft Pathology and the American Journal of Transplantation.| | PubMed
- A modified Hospital Frailty Risk Score for patients with cirrhosis undergoing abdominal operations.| | PubMed
- Advancing mouse models for transplantation research.| | PubMed